Nabla Bio
We use AI to design antibodies for intractable diseases
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University. Nabla Bio is a Y Combinator company (Summer 2020). YC-listed status: Active.
- Website
- nabla.bio
- Location
- Boston, MA, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Nabla Bio — Drug design platform combining de novo AI design and large-scale human-relevant testing to make drug development a true engineering discipline. · Service · Enterprise
Links
- Y Combinator profileycombinator